OP0125 TOFACITINIB IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: EFFICACY AND SAFETY...
OP0125 TOFACITINIB IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: EFFICACY AND SAFETY ANALYSIS FROM TREASURE REAL-LIFE DATA
About this item
Full title
Author / Creator
Kalyoncu, U. , Bilgin, E. , Erden, A. , Satiş, H. , Tufan, A. , Tekgoz, E. , Ateş, A. , Coşkun, B.N. , Yağiz, B. , Küçükşahin, O. , Yazisiz, V. , Kimyon, G. , Bes, C. , Ertenli, A.İ. and Kiraz, S.
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
Beyond the joints, rheumatoid arthritis (RA) may affect lungs. Especially the involvement of the paranchyme, RA-associated interstitial lung disease (RA-ILD), is a major cause of mortality and morbidity. Tofacitinib, an oral JAK 1/3 inhibitor, has been used increasingly in the management of rheumatoid arthritis (RA) in recent years. Recently, a cou...
Alternative Titles
Full title
OP0125 TOFACITINIB IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: EFFICACY AND SAFETY ANALYSIS FROM TREASURE REAL-LIFE DATA
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2593202115
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2593202115
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2021-eular.1236
